NCT00689520 - Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis | Biotech Hunter

Enrollment

241

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions

Venous Thromboembolism

Interventions

DRUG

tinzaparin

tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months

DRUG

acenocoumarol

tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months

Trial Locations (2)

Vascular surgery service. Hospital Creu Roja de l'Hospitalet, L'Hospitalet de Llobregat

Department of Vascular Surgery. Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat